Business consulting company Frost & Sullivan announced on Wednesday that WuXi AppTec has been awarded the 2025 Global Company of the Year Recognition in the contract research, development, and manufacturing organisation (CRDMO) industry for its outstanding achievements in enabling innovation, operational excellence, and customer impact.
Based in China, WuXi AppTec is a global pharmaceutical CRDMO that provides integrated drug discovery, development and manufacturing services across Asia, Europe and North America.
This award highlights WuXi AppTec's contribution to driving scientific and technological advancement through an integrated, end-to-end CRDMO model, enabling customers and partners worldwide to accelerate the journey from discovery to patient-ready therapies, Frost & Sullivan said.
Genentech reports first oral SERD to improve invasive disease-free survival in early breast cancer
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Pulmonary Fibrosis Foundation Launches New Five-Year Strategy: The PFF is ME
Acumen Pharmaceuticals begins open-label extension of Phase 2 Alzheimer's study
Incyte receives positive CHMP opinion for Minjuvi in relapsed or refractory follicular lymphoma
BioInvent secures EMA positive opinion for Orphan Drug Designation of BI-1808 in CTCL
IXICO wins GBP3.5m global Phase 3 Huntington's Disease trial contract
Japan's Ministry of Health, Labor and Welfare accepts Lundbeck's NDA for Vyepti (eptinezumab)
BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Cognision partners with Kynexis for use of COGNISION system in schizophrenia trial
CHMP issues positive opinion for DAWNZERA in hereditary angioedema